DOP2015000221A - Agentes quelantes de precursores de producto final de glicacion avanzada (age) - Google Patents
Agentes quelantes de precursores de producto final de glicacion avanzada (age)Info
- Publication number
- DOP2015000221A DOP2015000221A DO2015000221A DO2015000221A DOP2015000221A DO P2015000221 A DOP2015000221 A DO P2015000221A DO 2015000221 A DO2015000221 A DO 2015000221A DO 2015000221 A DO2015000221 A DO 2015000221A DO P2015000221 A DOP2015000221 A DO P2015000221A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- agents
- chemical precursors
- age
- disease
- glication
- Prior art date
Links
- 239000012707 chemical precursor Substances 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2015000221A true DOP2015000221A (es) | 2015-12-15 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2015000221A DOP2015000221A (es) | 2013-03-15 | 2015-09-08 | Agentes quelantes de precursores de producto final de glicacion avanzada (age) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (OSRAM) |
| EP (1) | EP2968403A1 (OSRAM) |
| JP (4) | JP2016512830A (OSRAM) |
| KR (1) | KR20150130492A (OSRAM) |
| CN (1) | CN105188718A (OSRAM) |
| AR (1) | AR095593A1 (OSRAM) |
| AU (2) | AU2014235500A1 (OSRAM) |
| BR (1) | BR112015023404A8 (OSRAM) |
| CA (1) | CA2906501A1 (OSRAM) |
| CL (1) | CL2015002624A1 (OSRAM) |
| CR (1) | CR20150545A (OSRAM) |
| DO (1) | DOP2015000221A (OSRAM) |
| EA (1) | EA201591733A1 (OSRAM) |
| HK (1) | HK1220607A1 (OSRAM) |
| IL (1) | IL241406A0 (OSRAM) |
| MA (1) | MA38487A1 (OSRAM) |
| MX (1) | MX2015012843A (OSRAM) |
| PE (1) | PE20151766A1 (OSRAM) |
| PH (1) | PH12015502019A1 (OSRAM) |
| SG (2) | SG11201506413PA (OSRAM) |
| TN (1) | TN2015000390A1 (OSRAM) |
| TW (1) | TW201521744A (OSRAM) |
| UY (1) | UY35441A (OSRAM) |
| WO (1) | WO2014150873A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| RU2020111589A (ru) * | 2017-08-31 | 2021-09-30 | Сайтосорбентс Корпорейшн | Снижение уровня конечных продуктов глубокого гликирования из биологических жидкостей |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| CA2444046C (en) * | 2001-04-18 | 2011-06-07 | Steven K. Burke | Use of colesevelam in reducing serum glucose |
| WO2005032563A1 (en) * | 2003-09-02 | 2005-04-14 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| KR20070004730A (ko) * | 2004-02-17 | 2007-01-09 | 다이나미스 테라퓨틱스, 인코포레이티드 | 프룩토스아민 3 키나아제 및 콜라겐 및 엘라스틴의 형성 |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| CN105017481B (zh) * | 2010-02-24 | 2018-10-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺 |
-
2014
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160024233A1 (en) | 2016-01-28 |
| SG10201707590XA (en) | 2017-11-29 |
| SG11201506413PA (en) | 2015-09-29 |
| TW201521744A (zh) | 2015-06-16 |
| JP2016512830A (ja) | 2016-05-09 |
| JP2020055850A (ja) | 2020-04-09 |
| JP2018135365A (ja) | 2018-08-30 |
| BR112015023404A8 (pt) | 2019-12-03 |
| PH12015502019A1 (en) | 2016-01-11 |
| CN105188718A (zh) | 2015-12-23 |
| CA2906501A1 (en) | 2014-09-25 |
| AU2019201259A1 (en) | 2019-03-14 |
| UY35441A (es) | 2014-10-31 |
| MX2015012843A (es) | 2016-08-08 |
| JP2022037143A (ja) | 2022-03-08 |
| CL2015002624A1 (es) | 2016-03-11 |
| IL241406A0 (en) | 2015-11-30 |
| CR20150545A (es) | 2015-12-01 |
| AU2014235500A1 (en) | 2015-11-05 |
| EA201591733A1 (ru) | 2016-01-29 |
| AR095593A1 (es) | 2015-10-28 |
| MA38487A1 (fr) | 2017-12-29 |
| KR20150130492A (ko) | 2015-11-23 |
| US20180265613A1 (en) | 2018-09-20 |
| PE20151766A1 (es) | 2015-12-11 |
| WO2014150873A1 (en) | 2014-09-25 |
| EP2968403A1 (en) | 2016-01-20 |
| TN2015000390A1 (en) | 2017-01-03 |
| BR112015023404A2 (pt) | 2017-07-18 |
| HK1220607A1 (zh) | 2017-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
| UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| TW201613901A (en) | New compounds | |
| UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| UY34037A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| MX2020010375A (es) | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
| WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| MX384259B (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. |